JANSSEN PHARMACEUTICAL K.K.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Macitentan, in Healthy Japanese Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Macitentan Dose 3
Drug: Macitentan Dose 1
Drug: Macitentan Dose 2
Drug: Placebo

First Posted Date: 2020-08-05

Last Posted Date: 2021-01-14

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 24

Registration Number: NCT04500808

Locations: 🇯🇵
Sumida Hospital, Tokyo, Japan

A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan

Active, not recruiting

Conditions: Palmoplantar Pustulosis

Interventions: Other: No intervention

First Posted Date: 2020-07-07

Last Posted Date: 2024-12-10

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 276

Registration Number: NCT04459507

Locations: 🇯🇵
Akita University Hospital, Akita, Japan
🇯🇵
Juntendo University Hospital, Bunkyo Ku, Japan
🇯🇵
Kyushu University Hospital, Fukuoka, Japan

and more 36 locations

A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Phase 3

Active, not recruiting

Conditions: Crohns Disease

Interventions: Drug: Guselkumab

First Posted Date: 2020-05-21

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 38

Registration Number: NCT04397263

Locations: 🇯🇵
Institute of Science Tokyo Hospital, Bunkyo ku, Japan
🇯🇵
KOKIKAI Tokatsu Tsujinaka Hospital, Abiko, Japan
🇯🇵
Hitachi General Hospital, Hitachi, Japan

and more 22 locations

A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and Older

Phase 1

Completed

Conditions: Healthy

Interventions: Other: Placebo
Biological: RSV Vaccine

First Posted Date: 2020-04-21

Last Posted Date: 2021-02-17

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 36

Registration Number: NCT04354480

Locations: 🇯🇵
Souseikai Hakata Clinic, Fukuoka, Japan

A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma

Phase 2

Active, not recruiting

Conditions: Salivary Gland Neoplasms

Interventions: Drug: Apalutamide
Drug: GnRH Agonist

First Posted Date: 2020-03-30

Last Posted Date: 2024-12-09

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 31

Registration Number: NCT04325828

Locations: 🇯🇵
National Cancer Center Hospital, Chuo Ku, Japan
🇯🇵
National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
🇯🇵
Kansai Medical University Hospital, Hirakata City, Japan

and more 4 locations

A Study to Evaluate the Different Doses of VAC52416 (ExPEC10V) in Japanese Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: ExPEC10V
Biological: Placebo

First Posted Date: 2020-03-12

Last Posted Date: 2021-01-20

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 24

Registration Number: NCT04306302

Locations: 🇯🇵
SOUSEIKAI PS Clinic, Fukuoka, Japan

A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

Phase 2

Completed

Conditions: Waldenstrom Macroglobulinemia

Interventions: Drug: Ibrutinib
Drug: Rituximab

First Posted Date: 2019-08-20

Last Posted Date: 2024-04-01

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 16

Registration Number: NCT04062448

Locations: 🇯🇵
National Cancer Center Hospital, Chuo-Ku, Japan
🇯🇵
National Hospital Organization Disaster Medical Center, Tachikawa, Japan
🇯🇵
Osaka Metropolitan University Hospital, Osaka, Japan

and more 6 locations

A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: Androgen-deprivation Therapy (ADT)
Drug: Bicalutamide
Drug: Abiraterone
Drug: Prednisolone
Drug: Docetaxel
Drug: Enzalutamide
Drug: Apalutamide

First Posted Date: 2019-07-26

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 979

Registration Number: NCT04034095

Locations: 🇯🇵
Akita University Hospital, Akita, Japan
🇯🇵
Juntendo University Hospital, Bunkyo Ku, Japan
🇯🇵
Tokyo Medical and Dental University Hospital, Bunkyo Ku, Japan

and more 74 locations

A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments

Phase 3

Terminated

Conditions: Polymyositis
Dermatomyositis

Interventions: Drug: Ustekinumab 6 mg/kg
Drug: Ustekinumab 90 mg
Drug: Placebo IV
Drug: Placebo SC

First Posted Date: 2019-06-11

Last Posted Date: 2024-05-13

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 51

Registration Number: NCT03981744

Locations: 🇯🇵
Fukushima Medical University Hospital, Fukushima, Japan
🇯🇵
Shinko Hospital, Hyogo, Japan
🇯🇵
Tokyo Medical and Dental University Hospital, Bunkyo-Ku, Japan

and more 29 locations

A Study of JNJ-64530440 in Healthy Japanese Male Participants

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: JNJ-0440
Drug: Placebo

First Posted Date: 2019-04-16

Last Posted Date: 2020-12-31

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 16

Registration Number: NCT03915886

Locations: 🇯🇵
Sumida Hospital, Tokyo, Japan

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy